Patents by Inventor Do-Woo Kwon

Do-Woo Kwon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230073516
    Abstract: The present disclosure provides an intraoral fast disintegrating formulation containing hemp oil extract or hemp powder extract as a raw material of the formulation, wherein the formulation contains a water-soluble binder, an inorganic material and a surfactant.
    Type: Application
    Filed: August 7, 2020
    Publication date: March 9, 2023
    Inventors: Hong-Ryeol JEON, Do-Woo KWON, Bong-Sang LEE, Su-Jun PARK, Myeongcheol KIL, Lee-Seul YANG
  • Patent number: 11266658
    Abstract: The present disclosure relates to an orally administered pharmaceutical formulation containing an inclusion complex formed as varenicline or a pharmaceutically acceptable salt thereof is included in cyclodextrin. The pharmaceutical formulation can improve convenience of medication by effectively masking the bitter taste of the drug and the irritation during swallowing, can provide the oxidation stability of varenicline and can improve the solubility of the drug.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: March 8, 2022
    Assignee: CTC BIO, INC.
    Inventors: Hong Ryeol Jeon, Do-Woo Kwon, Bong-Sang Lee, Seul Ki Meang, Su-Jun Park, Seong-Shin Kwak
  • Patent number: 11116769
    Abstract: The present disclosure relates to a film formulation for oral administration, containing tadalafil free base and a method of preparing the same, and a film may be provided with maximized dispersion stability of tadalafil free base in the film by the addition of a dispersion stabilizing agent in small amounts without unique fragrance or favor that may appear when other dispersion stabilizing agents known in the art are used, and an extremely low likelihood that a reagglomeration phenomenon of tadalafil free base particles will occur, and an amount of bubbles generated may be significantly reduced during a production process.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: September 14, 2021
    Assignee: CTC BIO, INC.
    Inventors: Hong Ryeol Jeon, Do-Woo Kwon, Bong-Sang Lee, Su-Jun Park, Bong-Geun Cha, Jun-Ki Kim, Jiyeong Han, Myeongcheol Kil
  • Publication number: 20200405714
    Abstract: The present disclosure relates to a film formulation for oral administration, containing tadalafil free base and a method of preparing the same, and a film may be provided with maximized dispersion stability of tadalafil free base in the film by the addition of a dispersion stabilizing agent in small amounts without unique fragrance or favor that may appear when other dispersion stabilizing agents known in the art are used, and an extremely low likelihood that a reagglomeration phenomenon of tadalafil free base particles will occur, and an amount of bubbles generated may be significantly reduced during a production process.
    Type: Application
    Filed: September 11, 2020
    Publication date: December 31, 2020
    Inventors: Hong Ryeol JEON, Do-Woo KWON, Bong-Sang LEE, Su-Jun PARK, Bong-Geun CHA, Jun-Ki KIM, Jiyeong HAN, Myeongcheol KIL
  • Publication number: 20200085818
    Abstract: The present disclosure relates to a film formulation for oral administration, containing tadalafil free base and a method of preparing the same, and a film may be provided with maximized dispersion stability of tadalafil free base in the film by the addition of a dispersion stabilizing agent in small amounts without unique fragrance or favor that may appear when other dispersion stabilizing agents known in the art are used, and an extremely low likelihood that a reagglomeration phenomenon of tadalafil free base particles will occur, and an amount of bubbles generated may be significantly reduced during a production process.
    Type: Application
    Filed: November 19, 2019
    Publication date: March 19, 2020
    Inventors: Hong Ryeol JEON, Do-Woo KWON, Bong-Sang LEE, Su-Jun PARK, Bong-Geun CHA, Jun-Ki KIM, Jiyeong HAN, Myeongcheol KIL
  • Publication number: 20200061078
    Abstract: The present disclosure relates to an orally administered pharmaceutical formulation containing an inclusion complex formed as varenicline or a pharmaceutically acceptable salt thereof is included in cyclodextrin. The pharmaceutical formulation can improve convenience of medication by effectively masking the bitter taste of the drug and the irritation during swallowing, can provide the oxidation stability of varenicline and can improve the solubility of the drug.
    Type: Application
    Filed: March 2, 2018
    Publication date: February 27, 2020
    Inventors: Hong Ryeol JEON, Do-Woo KWON, Bong-Sang LEE, Seul Ki MEANG, Su-Jun PARK, Seong-Shin KWAK
  • Publication number: 20190224208
    Abstract: The present invention relates to a pharmaceutical composition for treating, preventing or improving premature ejaculation, which is taken on demand prior to sexual activity, the composition comprising clomipramine hydrochloride in an amount of 14 to 16 mg, preferably about 15 mg, as an active ingredient. More preferably, the composition of the present invention further comprises pregelatinized starch and sodium starch glycolate. The pharmaceutical composition of the present invention can provide rapid onset of efficacy, reduce a dissolution (absorption) deviation according to the patient's gastrointestinal pH conditions and minimize side effects.
    Type: Application
    Filed: April 4, 2019
    Publication date: July 25, 2019
    Applicant: CTC Bio, Inc.
    Inventors: Hong-Ryeol Jeon, Do-Woo Kwon, Bong-Sang Lee, Seong-Shin Kwak, Sun-Ahe Lee, Hyun-Jung Park, Jeong-Hwa Yoo
  • Patent number: 10213437
    Abstract: The present invention relates to a pharmaceutical preparation for oral administration comprising, as an active ingredient, clomipramine or a pharmaceutically acceptable salt thereof; and a cation exchange resin and an anion polymer as a taste masking agent, wherein the pharmaceutical preparation can be orally administered even while comprising a pharmaceutically effective amount of clomipramine because the unique tastes of clomipramine, particularly, all of the bitter taste, spicy taste and burning taste are effectively masked, and thus the convenience of drug intake and portability is improved, and a method for manufacturing thereof.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: February 26, 2019
    Assignee: CTC BIO, INC.
    Inventors: Hong Ryeol Jeon, Do-Woo Kwon, Bong-Sang Lee, Su-Jun Park, Jiyeong Han, Myeongcheol Kil, Min Seop Kim
  • Patent number: 10045993
    Abstract: The present invention relates to a pharmaceutical preparation comprising entecavir as an active ingredient, wherein an antioxidizing agent is added to enhance stability of entecavir, and a method for preparing the same. According to the present invention, the invention has an effect that entecavir can be stably maintained in a pharmaceutical preparation containing a certain amount or more of moisture by adding the antioxidizing agent, thereby a pharmaceutical preparation can be provided as a formulation containing a certain amount or more of moisture, for example, an orally disintegrating film formulation.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: August 14, 2018
    Assignee: CTC BIO, INC.
    Inventors: Hong Ryeol Jeon, Do-Woo Kwon, Bong-Sang Lee, Su-Jun Park, Jiyeong Han, Myeongcheol Kil, Min Seop Kim
  • Patent number: D1055802
    Type: Grant
    Filed: June 8, 2023
    Date of Patent: December 31, 2024
    Assignees: Hyundai Motor Company, Kia Corporation
    Inventors: Hyung-Jin Park, Do-Woo Kwon
  • Patent number: D1055803
    Type: Grant
    Filed: June 8, 2023
    Date of Patent: December 31, 2024
    Assignees: Hyundai Motor Company, Kia Corporation
    Inventors: Hyung-Jin Park, Do-Woo Kwon
  • Patent number: D1060131
    Type: Grant
    Filed: June 8, 2023
    Date of Patent: February 4, 2025
    Assignees: Hyundai Motor Company, Kia Corporation
    Inventors: Do-Woo Kwon, Jae-Sup Park
  • Patent number: D1061342
    Type: Grant
    Filed: June 8, 2023
    Date of Patent: February 11, 2025
    Assignees: Hyundai Motor Company, Kia Corporation
    Inventors: Do-Woo Kwon, Jae-Sup Park
  • Patent number: D1064984
    Type: Grant
    Filed: April 28, 2023
    Date of Patent: March 4, 2025
    Assignees: Hyundai Motor Company, Kia Corporation
    Inventors: Chan-Joon Park, Do-Woo Kwon
  • Patent number: D1079583
    Type: Grant
    Filed: April 28, 2023
    Date of Patent: June 17, 2025
    Assignees: Hyundai Motor Company, Kia Corporation
    Inventors: Chan-Joon Park, Do-Woo Kwon
  • Patent number: D1086959
    Type: Grant
    Filed: June 8, 2023
    Date of Patent: August 5, 2025
    Assignees: Hyundai Motor Company, Kia Corporation
    Inventors: Hyung-Jin Park, Do-Woo Kwon
  • Patent number: D1097227
    Type: Grant
    Filed: June 8, 2023
    Date of Patent: October 7, 2025
    Assignees: Hyundai Motor Company, Kia Corporation
    Inventors: Woo-Joo Jung, Do-Woo Kwon
  • Patent number: D1097228
    Type: Grant
    Filed: June 8, 2023
    Date of Patent: October 7, 2025
    Assignees: Hyundai Motor Company, Kia Corporation
    Inventors: Woo-Joo Jung, Do-Woo Kwon
  • Patent number: D1120402
    Type: Grant
    Filed: June 8, 2023
    Date of Patent: March 24, 2026
    Assignees: Hyundai Motor Company, Kia Corporation
    Inventors: Woo-Joo Jung, Do-Woo Kwon
  • Patent number: D1127241
    Type: Grant
    Filed: June 8, 2023
    Date of Patent: May 19, 2026
    Assignees: Hyundai Motor Company, Kia Corporation
    Inventors: Woo-Joo Jung, Do-Woo Kwon